AIM: To explore the effects of peptide S-8300 from shark liver (S-8300) on liver function as well as in regulating immune functions in experimental injury models. METHODS: Mice were administered with different doses of S-8300 for four consecutive days, followed by mice injected with tetrachloromethane (CCl(4)) on d 3. The activity of ALT, AST, LDH, SOD and contents of MDA and GSH in the mice liver were tested. And mice were treated with Cy (100 mg/kg) at the beginning of the experiment to induce immunosuppression model. The S-8300 groups were treated with S-8300 seven days after the beginning of Cy administration. The effects of S-8300 on the formulation of serum hemolysin and the content of IL-2 in serum in the immunosuppression mice were observed. RESULTS: S-8300 obviously decreased the level of ALT (52.2+/-11.0 U/dL vs 135.9+/-6.5 U/dL, P<0.01), AST (67.5+/-6.9 U/dL vs 238.8+/-8.7 U/dL, P<0.01), LDH (155.1+/-46.8 U/dL vs 240.4+/-6.0 U/dL, P<0.01) and MDA (0.64+/-0.027 nmol/mg vs 1.06+/-0.040 nmol/mg, P<0.01) and increased SOD (24.51+/-1.01 U/mg vs 19.05+/-0.73 U/mg, P<0.01) and GSH (24.17+/-0.91 microg/mg vs 14.93+/-0.45 microg/mg, P<0.01) in mice liver damaged by CCl(4). S-8300 also markedly improved the formulation of serum hemolysin (0.094+/-0.005 A(540) vs 0.063+/-0.006 A(540), P<0.01) and increased the level of IL-2 (9.74+/-1.16 pg/mL vs 5.81+/-0.87 pg/mL, P<0.01) in serum of the immunosuppression mice. CONCLUSION: The results suggested S-8300 has significant hepatoprotective, immunomodulatory and inhibiting of lipid peroxidation activity.
AIM: To explore the effects of peptide S-8300 from shark liver (S-8300) on liver function as well as in regulating immune functions in experimental injury models. METHODS:Mice were administered with different doses of S-8300 for four consecutive days, followed by mice injected with tetrachloromethane (CCl(4)) on d 3. The activity of ALT, AST, LDH, SOD and contents of MDA and GSH in the mice liver were tested. And mice were treated with Cy (100 mg/kg) at the beginning of the experiment to induce immunosuppression model. The S-8300 groups were treated with S-8300 seven days after the beginning of Cy administration. The effects of S-8300 on the formulation of serum hemolysin and the content of IL-2 in serum in the immunosuppression mice were observed. RESULTS: S-8300 obviously decreased the level of ALT (52.2+/-11.0 U/dL vs 135.9+/-6.5 U/dL, P<0.01), AST (67.5+/-6.9 U/dL vs 238.8+/-8.7 U/dL, P<0.01), LDH (155.1+/-46.8 U/dL vs 240.4+/-6.0 U/dL, P<0.01) and MDA (0.64+/-0.027 nmol/mg vs 1.06+/-0.040 nmol/mg, P<0.01) and increased SOD (24.51+/-1.01 U/mg vs 19.05+/-0.73 U/mg, P<0.01) and GSH (24.17+/-0.91 microg/mg vs 14.93+/-0.45 microg/mg, P<0.01) in mice liver damaged by CCl(4). S-8300 also markedly improved the formulation of serum hemolysin (0.094+/-0.005 A(540) vs 0.063+/-0.006 A(540), P<0.01) and increased the level of IL-2 (9.74+/-1.16 pg/mL vs 5.81+/-0.87 pg/mL, P<0.01) in serum of the immunosuppression mice. CONCLUSION: The results suggested S-8300 has significant hepatoprotective, immunomodulatory and inhibiting of lipid peroxidation activity.
Authors: A Francavilla; P Ove; L Polimeno; M Coetzee; L Makowka; J Rose; D H Van Thiel; T E Starzl Journal: Cancer Res Date: 1987-11-01 Impact factor: 12.701